Overview
- Schlossberg disclosed her diagnosis in a Nov. 22 New Yorker essay, writing that doctors estimate she may have less than a year to live.
- Her illness was first flagged in May 2024 hours after childbirth, when testing showed a white blood cell count of about 131,000 per microliter.
- Her treatment has included chemotherapy, two bone-marrow transplants at Memorial Sloan Kettering, and enrollment in CAR-T cell therapy trials.
- Inversion 3 appears in roughly 1% to 1.5% of AML cases and is tied to misexpression of genes such as EVI1 and GATA2 that drive aggressive disease.
- Oncologists report no approved therapy specifically targets this subtype, though clinical trials of immune-based and targeted approaches are actively enrolling high-risk AML patients.